Metaxalone products, method of manufacture, and method of use
View Patent ↗Disclosed herein is a method of using metaxalone. In one embodiment, the method comprises obtaining metaxalone from a container providing information that metaxalone affects the activity of a cytochrome p450 isozyme. In another embodiment, the method comprises informing a user that metaxalone affects the activity of a cytochrome p450 isozyme. Also included are articles of manufacture comprising a container containing a dosage form of metaxalone, wherein the container is associated with published material informing that metaxalone affects activity of a cytochrome p450 isozyme. Also disclosed are a method of treatment and a method of manufacturing a metaxalone product.
1. A method of using metaxalone for treating a patient's condition, comprising
providing a patient with metaxalone; and
informing the patient or a medical care worker that metaxalone affects activity of a cytochrome p450 isozyme, and that administration of metaxalone with a substance that affects activity of a cytochrome p450 isozyme can affect plasma concentration, safety, efficacy or any combination thereof of metaxalone, the substance, or both.
2. The method of claim 1 , wherein the substance is an active agent with a narrow therapeutic index.
3. The method of claim 2 , wherein the substance is a substrate of CYP1A2, CYP3A4, CYP2B6, CYP2C19, CYP2D6, CYP2E1, or CYP2C9.
4. The method of claim 2 , wherein the substance is warfarin, phenytoin, fosphenytoin, thioridazine, or theophylline.
5. A method of using metaxalone to treat a patient's condition, comprising:
providing a patient with metaxalone; and
informing the patient or a medical care worker that a cytochrome p450 isozyme metabolizing metaxalone is CYP1A2 or CYP2C19 and that administration of metaxalone and a substance that is a substrate, inhibitor, or inducer of CYP1A2 or CYP2C19 can affect plasma concentration, safety, efficacy or any combination thereof of metaxalone, the substance, or both.
6. A method of using metaxalone to treat a patient's condition, comprising:
providing a patient with metaxalone; and
informing the patient or a medical care worker that metaxalone is an inhibitor, inducer, or substrate of a cytochrome p450 isozyme and administration of metaxalone with a substance that is an inhibitor, inducer, or substrate of the cytochrome p450 isozyme can affect the plasma concentration, safety or efficacy of the substance.
7. The method of claim 6 , wherein the cytochrome p450 isozyme is CYP1A2, CYP3A4, CYP2B6, CYP2C19, CYP2D6, CYP2E1, or CYP2C9.
8. The method of claim 6 , wherein the substance is an active agent with a narrow therapeutic index.
9. The method of claim 8 , wherein the substance is a substrate of CYP1A2, CYP3A4, CYP2B6, CYP2C19, CYP2D6, CYP2E1, or CYP2C9.
10. The method of claim 8 , wherein the active agent with the narrow therapeutic index is an inhibitor of the cytochrome p450 isozyme.
11. The method of claim 8 , wherein the active agent with the narrow therapeutic index is an inducer of the cytochrome p450 isozyme.
12. The method of claim 8 , wherein the active agent with the narrow therapeutic index is a substrate of the cytochrome p450 isozyme.
13. The method of claim 8 , wherein the substance is warfarin, phenytoin, fosphenytoin, thioridazine, or theophylline.
14. The method of claim 1 , wherein metaxalone is an inducer of the cytochrome p450 isozyme.
15. The method of claim 14 , wherein the cytochrome p450 isozyme is CYP1A2 or CYP3A4.
16. The method of claim 1 , wherein metaxalone is an inhibitor of the cytochrome p450 isozyme.
17. The method of claim 16 , wherein the cytochrome p450 isozyme is CYP1A2, CYP2B6, CYP2C19, CYP2D6, CYP2C9, CYP2E1, or CYP3A4.
18. The method of claim 1 , wherein metaxalone is a substrate of the cytochrome p450 isozyme.
19. The method of claim 18 , wherein the cytochrome p450 isozyme is CYP1A2 or CYP2C19.
20. The method of claim 1 , wherein the patient is a human patient.
21. The method of claim 1 , wherein the patient is a patient with a musculoskeletal condition.
22. The method of claim 1 , wherein the patient is a patient receiving metaxalone therapy.